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Background: Schistosome and soil-transmitted helminth (STH) infections are recognized as major global public
health problems, causing severe and subtle morbidity, including significant educational and nutritional effects in
children. Although effective and safe drugs are available, ensuring access to these drugs by all those at risk of
schistosomiasis and STHs is still a challenge. Community-directed intervention (CDI) has been used successfully for
mass distribution of drugs for other diseases such as onchocerciasis and lymphatic filariasis. A national control
programme is yet to be instituted in Kenya and evidence for cost-effective strategies for reaching most affected
communities is needed. This study evaluated the effectiveness and feasibility of the CDI strategy in the control of
schistosomiasis and STHs, in East Uyoma location, Rarieda district, a community of western Kenya that is highly
endemic for both infections.
Results: Pre-treatment prevalence of S. mansoni averaged 17.4% (range 5-43%) in the entire location. Treatment
coverage in different villages ranged from 54.19 to 96.6% by community drug distributor (CDD) records. Assessment
from a household survey showed coverage of 52.3 -91.9% while the proportion of homesteads (home compounds)
covered ranged from 54.9-98.5%. Six months after one round of drug distribution, the prevalence levels of S.
mansoni, hookworm and Trichuris trichura infections were reduced by 33.2%, 69.4% and 42.6% respectively.
Conclusions: This study shows that CDI is an accepted and effective strategy in the mass treatment of
schistosomiasis and STH infections in resource constrained communities in Kenya and may be useful in similar
communities elsewhere. A controlled trial comparing CDI and school based mass drug administration to
demonstarte their relative advantages is ongoing.Background
Schistosome and soil-transmitted helminth (STH) infec-
tions cause a huge burden of disease in the developing
world [1], and have been associated with significant
educational and nutritional effects [2,3]. School age
children suffer from subtle morbidity such as anemia,
chronic pain, diarrhea, exercise intolerance, growth stunt-
ing, undernutrition and impaired cognitive development,
leading to poor school performance [3]. In children and
adults, schistosomiasis mansoni can have nonspecific
clinical manifestations such as bloody diarrhea and* Correspondence: pmwinzi@kemricdc.org
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reproduction in any medium, provided the orabdominal discomfort, and if untreated can lead to
serious liver complications. While this burden is difficult
to measure, deaths due to schistosomiasis have been
estimated as high as 200,000 per year [3].
In Kenya, over 6 million people are estimated to be
infected [1] and many more are at risk. The highest
infection rates are found in adolescents aged 10–19 years,
but adult workers in rural areas who are employed in
activities associated with water contact are also affected
[4-6]. Overall, the prevalence of schistosomiasis ranges
from 5% to over 65% in communities in Kenya and
contributes to significant morbidity [5-8]. In the Nyanza
region, schistosomiasis is largely associated with Lake
Victoria [9]. There are still many areas where the true
burden with schistosomiasis is not well known as diseaseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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schistosomiasis in this setting [10-12] should continue to
be encouraged. Prevalence levels among school children
along the Lake shores ranged between 29-94% [10]. In
another study, more than 50% of the children in schools
located less than 1 kilometer from the lake were positive
for S. mansoni infection. This prevalence decreased with
increasing distance from the lake [9].
Often, schistosome infections co-occur with STHs. In
Kenya, the prevalence of STHs is prominently attributed
to Ascaris lumbricoides, hookworm and Trichuris tri-
chiura [13,14]. It is estimated that approximately 10 mil-
lion Kenyans are infected with STHs and over 12 million
people living in rural endemic areas in the country are at
risk of infection with these parasites. In Nyanza, up to
50% of school going children were infected with hook-
worm, ascarids, or trichurids [14] but there was no effect
of lake proximity in the overall distribution of these
STHs [9,14].
Despite the importance of schistosomiasis and STHs in
Kenya, a National Control Program for the community
has not been instituted. However, a national deworming
program targeting school aged children was launched by
both Ministers of Basic Education and Public Health and
Sanitation, and implemented in 45 districts (total dis-
tricts 254) in year 2009. Currently, school-based
deworming is the primary approach being used for mass
treatment of schistosomiasis and STHs and has been
supported in a few areas in the country, mostly by local
and international non-governmental organizations
(NGOs). However, this approach is limited by low school
enrolment in Kenya despite the introduction of free uni-
versal primary education in 2002 as poverty-related indir-
ect costs prevent attendance by many children. Effective
control by the school-based strategy may not be possible
if other infected members of the community are not trea-
ted, such as fishermen, farmers in irrigation schemes, sand
harvesters and mothers of child bearing age who can have
high levels of infection but are not reached by school-
based treatment programs. Involvement of communities,
both for implementing school-based treatment and for in-
creasing coverage to all those at risk, has not been effect-
ively employed.
To improve access to treatment at affordable and sus-
tainable costs and, where possible, to improve existing pro-
grams, community-directed intervention (CDI) has been
presented as an alternative strategy for control of schisto-
somiasis and STHs. The CDI approach has been tried in
several settings [15-18] and has worked successfully in
many countries for the African Programme for Onchocer-
ciasis Control (APOC) [19-21] as well as for lymphatic fil-
ariasis control along the Kenyan coast [22,23].
Effective and safe drugs for treatment of STHs are
available in Kenya. However, drugs for treatment ofschistosomiasis are not available in the health facilities in
the country, and STH treatment is intermittently avail-
able in health facilities. Most individuals at high risk of
morbidity do not have access to treatment because of the
paucity of health infrastructure, lack of awareness about
the disease, or cost. Therefore it is pertinent to evaluate
if CDI would increase access to treatment among com-
munity members as well as increase coverage in school
age children. We used the CDI approach for treatment
against schistosomiasis and STHs in East Uyoma loca-
tion of Western Kenya, an area along the shores of Lake
Victoria highly endemic for schistosomais and STHs, to
test CDI acceptability and effectiveness in reducing dis-
ease prevalence and burden.
Methods
Study area
This study was conducted in a rural part of Nyanza
Province, Western Kenya in Madiany Division, East
Uyoma location, within the Health and Demographic
Surveillance System (HDSS) platform. This HDSS was
established in September 2001 by the Kenya Medical
Research Institute and the CDC (KEMRI/CDC) [24];
(Figure 1). East Uyoma location has 25 villages. This
study area borders Lake Victoria where earlier surveys
had identified schistosomiasis prevalence levels between
30% to 80% among highly exposed individuals [5,6,9].
Study design
Mapping and census of study area
Village representatives (VR) who had participated in pre-
vious studies in the area were asked to help with a map
updating exercise. This included confirming compound
IDs and mapping any new compounds that had been
established since the previous mapping by the KEMRI/
CDC HDSS program. The coastline, which changes over
time due to the receding waters of Lake Victoria, was
also updated. A database identifying compounds, com-
pound heads, and households in each compound was
created and updated maps of the East Uyoma were gen-
erated, showing locations of schools and clinics, village
boundaries, and other relevant features like rivers or
creeks (Figure 1). This database was used to determine
geographical treatment coverage and for mapping disease
distribution. In total, there are 25 villages in the study
area with 2046 compounds and an average 4.05 house-
holds per compound. After mapping the village, trained
CDDs conducted the village census to determine the
number of praziquantel and albendazole tablets required
in his/her allocated area. Each CDD was assigned an
average of 60 compounds. Compound heads were con-
sented for inclusion of their home compounds in the
census in preparation for drug distribution. The census
Figure 1 Map of East Uyoma in western Kenya showing study villages along the shores of Lake Victoria.
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census booklets
Prevalence survey
Parasitological surveys were conducted by the research
team. Pre-treatment prevalence levels of S. mansoni
infections, STH infections and anemia were assessed
among standard 4 children aged 9–10 years old in all 10
schools in the study area. Prevalence of infection in
school age children was used as a proxy to estimate
baseline community prevalence and subsequent treat-
ment coverage [25] . The initial parasitological survey
was followed by a post-treatment survey in May 2008,
six months after the baseline survey and drug distribu-
tion. Through the school leadership, parents of pupils in
class 4 were requested to come to the school compound
to be informed about the study and to provide consent
for their children’s participation. Only children of parents
who agreed to come to school and gave informed con-
sent and children who gave assent were included in the
study. Up to 99% of parents signed the consent forms. A
total of 492 children were included in the study followingconsent by parents and assent by the children. To assess
parasite infections at each survey time, children were
asked to provide a single stool sample. Two slides were
prepared from each stool sample using the Kato-Katz
method and each slide was read by an experienced mi-
croscopist. Blood was collected by finger-stick to evalu-
ate hemoglobin (Hb) levels using a Hemacue
(Ängelholm, Sweden). Socioeconomic data were also col-
lected from parents of participating children using stan-
dardized questionnaires in order to determine if
prevalence and CDI uptake levels were related to socio-
economic status.
Community drug distributors (CDD)
The CDDs were lay persons from the study area who
volunteered for this role. CDDs were trained to adminis-
ter informed consent during census and drug distribu-
tion exercises, to distribute the drugs, and to report back
to the health facility and researchers. A training curricu-
lum modeled on the Kenya Ministry of Health training
kit for teachers was developed and used for the training
of CDDs. Each CDD received a manual that included
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STHs, treatment guidelines, the goals of CDI and the
role of a CDD. CDDs were trained for conducting a
census by the research team and local Ministry of Health
workers. The CDDs obtained consent from compound
heads for the census and of all community members for
treatments in the door-to-door drug distribution. The re-
search team administered all other consent, including
that for the baseline survey among parents and parasito-
logical survey in children.
Drug distribution
Praziquantel and albendazole were used for the inte-
grated treatment of schistosomes and STH infections,
respectively, among residents aged≥ 5 years, using trained
community drug distributors (CDD).
Drug distribution treatment was recorded in the same
booklet used for the census, allowing for easy follow-up
by the CDDs. Doses of drugs were distributed door-to-
door to individuals based on their height, excluding
children under 5 years old. The drug distribution exer-
cise carried out in December 2007-February 2008
was disrupted by the post-election skirmishes of late
December 2007 –January 2008, but some CDDs who
had not completed the exercise were able to resume in
February 2008.
Praziquantel dosage determination by height
We modified the tablet pole [26,27] to a version that was
light and foldable and therefore very easy to carry by
CDDs. The tablet pole had a magnet at the hinge which
held the pole firmly straight when unfolded during use.
The pole was color coded for easy determination of drug
dosage by the CDDs. CDDs recorded the number of
drug tablets given to each individual against height by
color code on the pole.
Data analysis
Quantitative data were entered and summarized using
MS Access and Excel. Data were analyzed in MS Access,
GraphPad Prism and Excel. Pre-treatment and post-
treatment prevalence and infection intensity levels were
compared using Chi-square and nonparametric t-tests.
P values < 0.05 were considered significant.
Ethical considerations
This study was reviewed and cleared by the Kenya
National Ethics Committee and permission was obtained
from District (Bondo) and Divisional (Uyoma) Adminis-
tration as well as District Education Officers. The project
was then introduced to schools through school heads
and to the community during community meetings nor-
mally called by the location chiefs and village heads.
These traditional “barazas” (Chief ’s meeting) were usedfor project introduction and information dissemination
so as to keep within the normal community structures to
ensure sustainability. No parallel community gatherings
were introduced. During these meetings, health education
was provided to the community. Community members




Results from the census exercise completed by CDDs
in October 2008 indicated that there were 5987 adults
(persons over 18 years; 57.9% of the population), 3677
(35.5%) children over 5 years and 683 (6.6%) were
children under five in East Uyoma, bringing the total
population to 10347 and population eligible for treat-
ment to 9664. East Uyoma Location had 25 villages,
some of which were sub-divided for our drug distribu-
tion convenience, and about 2046 home compounds.
According to the 2009 national census data from Kenya
Bureau of Statistics, the community had a total popula-
tion of 15281 which included 7562 (49.5%) males and
7719 (50.5%) females, with 9.6% (n = 1467) of the popula-
tion being children under 5 and the population eligible
for mass treatment being 13814. These data suggest that
the CDD census missed about 4934 persons, represent-
ing 32.3% of the population.
Socio-economic survey
Areas endemic for schistosomiasis and STH infections
are usually associated with inadequate sanitation and
generally lower living standards. To establish the socioe-
conomic and water contact levels in relationship to CDI
uptake, a socio-economic questionnaire was adminis-
tered to parents of children in class 4 of all 10 primary
schools in the East Uyoma location. Of 404 respondents,
the majority of community members (95.3%) lived
on their own land and practiced subsistence farming.
Almost everyone (98.3%) in the community had daily
contact with Lake Victoria (34.2%), a pond/dam (45.4%)
or creek/river (18.6%), all potential schistosomiasis trans-
mission sites. Only 36.2% of respondents had access to
piped water or a well, whether in their homes (9.9%) or
in public/community-owned water sources (26.3%). Sani-
tation was generally poor. While 60.3% of people sur-
veyed had pit toilets, 30.2% did not have access to any
sanitation facility and used the open ground for
defecation. (Table 1). Less than 2% of the study popula-
tion owned either a car, refrigerator or had electricity,
but a large proportion owned radios (85.1), mobile (cell)
phones (35.2%) or bicycles (70.5%). Only 9.7% of people
who answered the survey had television sets in their
homes. The majority of the houses had dirt/earth floor-
ing (82.4%). Natural/grass roofing was utilized on 42.2%
Table 1 Relationship between socio-economic characteristics and prevalence of schistosomiasis and geohelminthic
infections in school children
Socio-economic data n= 404 Frequency and distribution of parasites% (n)
N % S. mansoni% (n) Any STH (HW, TT, Asc)% (n)
Water Contact: Lake Victoria
Everyday 138 34.2 18.25 (23) 14.96 (19)
Sometimes 82 20.3 25.00 (17) 20.59 (14)
Rarely 64 15.9 12.96 (7) 25.93 (14)
Never 119 29.5 12.62 (13) 21.36 (22)
Pond or Dam
Everyday 183 45.4 10.49 (17) 17.79 (29)
Sometimes 59 14.6 20.75 (11) 20.75 (11)
Rarely 35 8.7 17.24 (5) 34.48 (10)
Never 120 29.8 24.00 (24) 17.00 (17)
Creek or River
Everyday 75 18.6 17.39 (12) 15.94 (11)
Sometimes 55 13.6 22.73 (10) 25.00 (11)
Rarely 43 10.7 14.63 (6) 21.95 (9)
Never 220 54.3 15.14 (28) 19.46 (36)
Drinking water
Own pipe 23 5.7 8.70 (2) 17.39 (4)
Public pipe 106 26.3 11.32 (12) 20.75 (22)
Own Well 17 4.2 23.53 (4) 5.88 (1)
Public well 52 12.9 5.77 (3) 15.38 (8)
Rain water 65 16.1 10.77 (7) 6.15 (4)
River/canal 85 21.1 12.94 (11) 12.94 (11)
Other 121 30.0 18.18 (22) 11.57 (14)
Type of toilet
Own flush 2 0.5 50.00 (1) 0
Shared flush 1 0.3 0 0
Pit latrine 244 60.3 12.30 (30) 17.62 (43)
VIP 1 0.3
Bush/field 146 36.2 18.49 (27) 19.05 (24)
other 5 1.2 0 0
Housing
Electricity 7 1.7 0 0
Fridge 1 0.3 0 0
Car 1 0.3 0 0
Telephone 142 35.2 17.65 (21) 21.74 (25)
Radio 344 85.1 17.06 (50) 19.73 (58)
Bicycle 285 70.5 18.57 (44) 18.91 (45)
TV 39 9.7 11.54 (3) 23.08 (6)
Motor bike 3 0.7 0 19.54 (68)
Domestic worker 27 6.7 9.09 (2) 22.73 (22)
SES quintile (1–4) 142 42.13 16.20 (23) 22.54 (32)
SES quintile (5) 195 57.86 15.38 (30) 18.46 (36)
Socio-economic data was obtained by administering questionnaire to parents. HW – Hookworm, T.T – T. trichura, Asc. – A. lumbricoides, SES –socioeconomic status.
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Previous interventions for parasitic diseases in the area
had resulted in limited success with 41.7% of survey par-
ticipants having bed nets in their homes, 68.4% of those
nets had been treated regularly. No infections were
found among the few children from families that had
electricity or owned a car or a refrigerator. However, we
did not find any relationship between overall socio-
economic status Z scores and infection levels in individ-
ual children, prevalence level by village, or CDI coverage.
This is perhaps because all the villages were close to
the lake (all within 5KM of the shore) and exposure
levels among children were not significantly different.
Disease distribution
Pre-treatment prevalence levels of S. mansoni in East
Uyoma schools ranged from 5% to 43.2% with an average
prevalence of 17.8%. Mean intensity (± SD) of eggs per
gram (EPG) was 166.8 ± 295.1 (range 12–1560; CI: 99.8 -
222.0). At the six month follow-up, 576 children were
surveyed. S. mansoni infections were detected in 38 out
of 84 new children who had recently joined the schools
and had not participated in the baseline survey. This mi-
gration was mostly caused by the post-election violence
and led to higher post-treatment prevalence levels in two
schools. When the comparison was limited to children
surveyed at baseline, there was a 33.2% reduction in
mean school prevalence of S. mansoni (P =0.04), a 69.4%
reduction in hookworm prevalence (P = 0.003), a 1.8%
decrease in prevalence of A. lumbricoides (NS) and a
42.6% reduction in T. trichiura prevalence (P = 0.027)
(Figure 2A). Mean intensity (± SD) of S. mansoni infec-
tion EPG after mass treatment was reduced to
60.3 ± 70.9 (range 12–322; CI: 7.6-46.9). Mean Hb levels
were 12.5 ± 1.9 g/dl and ranged from 5.1 g/dl to 18.5 g/
dl. Hemoglobin levels increased by 0.4 g/dl from base-
line, but the difference was not statistically significant
(Figure 2B).
Household survey
The household survey was used to assess treatment
coverage and occurrence of side effects. Sixteen villages
were randomly selected for a household survey and
assigned to 10 interviewers who walked door-to-door
administering post-treatment questionnaires to house-
holds. The interviewers were CDDs from different
villages from those they were assigned to survey. Each
interviewer was asked to randomly interview 50 com-
pounds in each selected village, but an average of only
35.7 (range 13–50) compounds were visited per village,
totalling 785 compounds. At the end of 2 weeks, records
were retrieved from the interviewers and analyzed.
Reasons for the low coverage of compounds by some of
the CDDs included interviewer’s inability to access somehomes and the slow pace and poor performance of some
of the community interviewers. According to the CDD
house-hold survey records, the average age of the head
of compound was 53.8 years (31.1 -59.6 years). The 785
compounds included in the household survey had an
average (± SD) 4.0 households and 12.6 ± 2.6 persons
per compound. An average of 7.9 ± 2.0 persons per
compound reported receiving treatment, 5.9 ± 3.1 per-
sons reported not receiving treatment and an average
of 1.2 ± 0.4 persons per compound were reported absent.
Treatment coverage
Treatment coverage for praziquantel and albendazole
was assessed from CDD registers, but since coverage
values obtained from the community registers of the
CDDs may be unreliable[28], coverage was also assessed
through a household survey using a questionnaire for
parents/household heads. The questionnaires were admi-
nistered in randomly selected households in the commu-
nities and administered to all members of the household
present at the time of the survey. A total of 8103 persons
were treated according to CDD registers. Treatment
coverage was calculated as the total number of persons
treated divided by total eligible population (persons over
5 years of age) and expressed as a percentage. The per-
centage of persons treated according to CDD records
ranged from 54.2% - 96.6% in individual villages
(77.5%± 16.8; n = 8103). In six villages (Matera, Ukunja,
Migowa, Okela, Osewere, and Kakremba), incomplete
CDD records were returned after one CDD found a dif-
ferent job before completing the treatment exercise
(Matera village); 4 CDDs were offered paid jobs as elec-
tion clerks in the area before they could complete the
treatment exercise and one CDD migrated away from
the area (Kakremba village). Other volunteers completed
the exercise in those areas after our surveys. Coverage in
other areas where treatment was completed ranged from
52.1% - 90.3%. There was a significant difference be-
tween coverage by CDD records, 77.5 ± 16.8%, and
coverage per total population determined by the house-
hold survey, 58.2% (P < 0.01; ANOVA)), which was also
comparable to the coverage when official national census
population data were used as the denominator (53.0% of
the total population and 58.6% of the eligible popula-
tion). Because the area was mapped before the treatment
exercise and all the home compounds in the location
were recorded, it was possible to estimate coverage from
the CDD records by analyzing the number of com-
pounds visited. This revealed that even though a CDD
record may show very high coverage, such coverage was
only based on those compounds that had been visited
and recorded by the CDD and not necessarily all com-
pounds. According to this analysis, Nyamboi and
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Figure 2 Comparison of parasite prevalence levels following one round of mass drug distribution. A. Prevalence levels for S. mansoni,
hookworm, A.lumbricoides and Trichuris trichura compared before and after treatment with praziquantel and albendazole. Error bars represent
standard deviation (SD) of means. * represents significant change in prevalence following treatment B. Haemoglobin levels compared before and
after treatment.
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(Table 2).
Side effects
Praziquantel is generally safe and usually only causes
minor side effects that usually resolve with minimal
management. Side effects following treatment were
recorded during the household survey. Reported side
effects were minor with 12.7% (n = 279), 34.2% (n = 752),
4.7% (n = 103) and 0.3% (n = 21) of those treated report-
ing diarrhea, fatigue, abdominal pain and vomiting,
respectively. Fatigue was the most common reported side
effect. Overall, 48.7% of those treated reported one or
more of these minor side effects.
Drug costs
The financial cost of praziquantel for treated persons
was $9,865.85, for an average cost per treatment of
$0.98, while the cost for albendazole treatment was $0.23
per dose. These drugs were purchased by the project be-
cause at the time of the study, free or subsidized drugs
were not available from the public health sector. Eco-
nomic costs associated with the drug distribution were
not evaluated as part of this study.
Discussion
With renewed interest in the control of schistosomiasis
and other neglected tropical diseases (NTDs), both by
global sponsors and governments in endemic regions,
evidence based data on cost effective strategies for mass
drug administration are needed to inform control and
elimination program managers. Adhering to strategicguidelines issued by the World Health Organization, the
main approach has been to use school-based mass treat-
ment for controlling schistosomiasis in highly endemic
areas. However, it is recognized that this approach leaves
out other members in the community who are also
infected and who may be contributing to continued
transmission. In recent years, community based treat-
ment has been tested as an alternate approach but
community-level programs may be limited by inadequate
health care infrastructure at the primary level in many
areas of Africa [29,30]. In Kenya, although the govern-
ment recognizes the importance of local interventions
and having policies for preventive approaches for health
care, allocation of health resources has been skewed in
favor of tertiary and secondary facilities that offer cura-
tive services. This approach ignores rural health facilities
that are the first point of patient contact and provide the
bulk of the healthcare services [31].
As an example of a primary health care level program,
CDI has been evaluated and found to be highly success-
ful in reaching persons at risk of disease within the com-
munity [32]. CDI emphasizes the significant role of
communities as lead partners and is the fundamental fac-
tor that has been responsible for the success of APOC.
Systematic reviews have shown that the use of commu-
nity or lay health workers who are trained in the context
of the intervention but who have no formal professional
or tertiary education in preventative health care, showed
promising benefits. Compared with usual care, lay health
workers increased the uptake of childhood immunization,
promoted breastfeeding, reduced childhood mortality and
morbidity from common childhood illnesses, and









Agege 35 67.7 710 71.1 75.9
Andom A 26 87.7 372 61.3 52.1
Andom B 22 90.5 227 54.2 57.4
Chianda 26 52.3 231 80.1 74.8
Got-Kachola 21 85.6 616 89.6 90.3
βKakremba 50 74.6 438 95.7 20.1
Kasiri 16 71.9 679 80.3 ND
Kayundi 49 38.1 162 75.9 ND
Kunya 28 67.6 558 77.4 61.4
Magombe 25 77.5 612 91.1 89.0
Maranba 51 61.6 397 54.9 62.2
βMatera 50 67.2 449 26.7 ND
βMigowa 30 59.7 451 86.9 37.3
Mituri 21 80.4 503 73.6 71.3
Mochi 98 77.8 394 98.5 ND
Nyagunda 26 64.2 552 73.2 62.4
Nyamasore A 21 50.7 196 61.2 ND
Nyamasore B 30 64.6 173 77.5 ND
Nyamboi 48 23.4 71 77.5 ND
Ochienga 50 90.0 446 68.6 ND
Odede 25 85.2 388 93.3 55.9
Okela 25 63.3 553 81.2 61.4
βUkunja 50 77.5 320 95.6 35.7
βOsewre 35 91.9 235 96.6 49.0
Wayaga 13 81.4 614 94.9 ND
Total or Average 871 67.53 10347 77.47 58.1641
α P= 0.0047 (Paired t) for comparison between CDD record for coverage and independent household survey.
β CDDs quit exercise before completing drug distribution.
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study by Ndyomugyenyi and Kabatereine [18], integrated
CDI achieved higher treatment coverage (85%) for prazi-
quantel and mebendazole compared to a school-based
treatment approach (79%) for children aged 5–14 years.
Moreover, CDI is able to reach other at risk groups in the
community outside of the school system. However, more
controlled studies comparing the CDI and school-based
mass-drug administrations in endemic areas are needed.
The aim of this project was to pilot and evaluate the
CDI approach for treatment against schistosomiasis and
STHs in a rural setting in Nyanza Province, western
Kenya, which is outside the APOC zone and therefore
untested for CDI. In the current study, the CDDs visited
67.5% of the mapped compounds and achieved an overall
coverage of 58.2% as determined by household survey.
The effectiveness of CDI coverage was influenced by sev-
eral factors. Coverage depended on accurate mapping ofthe targeted treatment area by compound because CDD
records were based on only the compounds that the
CDD had visited; as a result, they overestimated coverage
(Table 2). Further, sociopolitical factors may have influ-
enced the study results and the success of CDI. This CDI
coincided with the 5-yearly election period in Kenya,
which presented a difficult challenge to many CDDs.
The political tension in the community affected the gen-
eral acceptability of CDDs in homes where they were
perceived to be of different political persuasions. More-
over, the community focus on election campaigns led to
increased absenteeism from homes. Even with these diffi-
culties, many villages were able to achieve appreciable
coverage levels.
In this study, the praziquantel cost was $0.98 per deliv-
ered treatment and the albendazole cost was $0.23 per
delivered treatment. These drugs were not provided by
the donor-subsidized public health sector where it would
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cheaper or even free. Reducing the cost of praziquantel
should be an encouragement to both private and public
sectors to implement mass drug distribution programs.
These results confirm that praziquantel is well tolerated,
causing only minor side effects. However, community
wide rumors on drug reactions can adversely affect well
organized mass treatments. To help alleviate fears of
drug reactions in communities and promote MDA com-
pliance, large-scale control programmes should include
pharmacovigilance studies as part of ongoing monitoring
and evaluation strategies. Detailed pharmacovigilance
data that are disseminated back to the community will
provide accurate information to communities about the
exact nature, extent and cause of side effects as well as
help to discriminate true side effects from other under-
lying conditions and exaggerated rumors about drug
reactions.Conclusion
The impact of this one round of drug distribution in a
troubled area confirms the feasibility of using CDI for
the control of helminth infections in endemic communi-
ties. A recently concluded multi-country study on CDI
in areas already participating in onchocerciasis control
[16] has demonstrated that the CDI process/approach
can be effective and feasible for integrated delivery of dif-
ferent health interventions in rural Africa [16,19]. Future
testing of CDI should be aimed at testing how CDI may
be used widely for multiple interventions to strengthen
primary health care at the national level and could inte-
grate with other established control programs such as
HIV, TB, malaria and maternal and child health (MCH)
programs. As the Kenya Ministry of Health continues to
roll out the Community Health Strategy, the future role
of CDDs will be taken up by community health workers
and be more integrated with other community level
health activities. It will be helpful to evaluate these devel-
opments as they occur. Currently, we are conducting
studies to test how elements of the CDI may be used to
strengthen the Kenya Ministry of Health’s community
strategy and thereby improve primary health care in
rural Kenya. Similar studies in the same setting are com-
paring community wide treatment to school based treat-
ment in a randomized controlled trial. We are also
preparing reports on qualitative findings
describing community acceptability of the CDI
approach in this setting. This pilot study paves the way
for larger scale trials to compare community wide treat-
ments to school-based strategies in the country.Competing interests
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